Japan Launches ‘Safety Net’ Initiative To Resolve Drug Lag With The West (Part 2 of 2)
This article was originally published in PharmAsia News
Executive Summary
[Editor's note: This is part two of a two-part feature on Japan's Pharmaceuticals and Medical Devices Agency risk management pilot program. Part one outlined the initiative. Part two discusses PMDA's intentions for the initiative and industry reaction in Japan]
You may also be interested in...
Japan's MHLW Panel Awards Orphan Status To Century Medical Artificial Heart, Panasonic PDT Semiconductor Laser
TOKYO - Japan's Pharmaceutical and Food Sanitation Council's subcommittee on medical devices and in vitro diagnostics has approved two devices for orphan diseases and three others, Takeshi Baba, manager of the General Affairs Division of the Ministry of Health, Labor and Welfare's Pharmaceutical and Food Bureau told PharmAsia News Dec. 12
Japan's MHLW Panel Awards Orphan Status To Century Medical Artificial Heart, Panasonic PDT Semiconductor Laser
TOKYO - Japan's Pharmaceutical and Food Sanitation Council's subcommittee on medical devices and in vitro diagnostics has approved two devices for orphan diseases and three others, Takeshi Baba, manager of the General Affairs Division of the Ministry of Health, Labor and Welfare's Pharmaceutical and Food Bureau told PharmAsia News Dec. 12
Japan Launches ‘Safety Net’ Initiative As PMDA Looks To Resolve Drug Lag With The West (Part 1 of 2)
TOKYO - Japan's Pharmaceuticals and Medical Devices Agency has started a new pilot program for risk management, tentatively being called the "product management" initiative. Under the initiative, a group will be created within PMDA's Office of Safety to oversee a new drug throughout its life cycle. Initial plans called for only a handful of drugs being involved. The agency hopes to finish the pilot program within six months, in time for the initiative to be operational some time in the spring